. Author manuscript; available in PMC: 2014 Apr 1.

Published in final edited form as: Nat Rev Clin Oncol. 2013 Feb 5;10(4):211–224. doi: 10.1038/nrclinonc.2013.5

Table 3.

Most-frequently used agents in platinum-resistant disease

Agent	Response rate (%)	PFS (months)	OS (months)	Side effects	Comments
Pegylated liposomal doxorubicin^{61, 62}	10–20	3–4	10–12	Hand–foot syndrome; mucositis	Most frequently prescribed as every 4 weeks schedule
Topotecan^{61, 63}	12–18	3–4	10–12 mos.	Myelosuppression	Daily for 5 days or weekly administration used
Docetaxel⁶⁰	22	3.5	12.7 mos.	Myelosuppression	Single GOG trial with very good results
Gemcitabine^{62, 103}	15	4–5	11.8–12.7 mos.	Myelosuppression	Also data with platinums in resistant disease¹⁰⁴; approved for platinum-sensitive disease with carboplatinum
Pemetrexed¹⁰⁵	15–21	2.9	11.4 mos.	Myelosuppression	Not approved in ovarian cancer
Etoposide^{106, 107}	6–27	4–5	10–11 mos.	Myelosuppression	Activity, dose and population dependent
Paclitaxel^64–67	10–30	4–6	13 mos.	Myelosuppression; Neuropathy	Usually administered weekly in this setting
Nab-paclitaxel¹⁰⁸	23	4–5	17.4 mos.	Myelosuppression; neuropathy	Not approved in ovarian cancer
Bevacizumab⁷⁹	21	4.7	17	Hypertension; proteinuria; thrombosis	Not approved in ovarian cancer in the USA; pivotal phase II supporting phase III front-line and recurrence investigation
Chemotherapy^* +/−bevacizumab⁵⁸	13 vs 31	3.4 vs 6.7	Pending	Adding bevacizumab increased hypertension; proteinuria	OS pending; bevacizumab not approved in ovarian cancer

Abbreviations: GOG, Gynecologic Oncology Group; PFS, Progression-free survival; OS, overall survival.

Allowable chemotherapy regimens in this study were paclitaxel (weekly), pegylated liposomal doxorubicin; topotecan (2 infusion styles: weekly, daily for 5 days).